Elevance Health (ELV) Scheduled to Post Earnings on Wednesday

Elevance Health (NYSE:ELV – Get Rating) is scheduled to issue its quarterly earnings data before the market opens on Wednesday, January 25th. Analysts expect the company to announce earnings of $5.21 per share for the quarter. Parties that are interested in participating in the company’s conference call can do so using this link.

Elevance Health Stock Performance

Shares of Elevance Health stock traded up $0.58 during trading on Tuesday, hitting $478.52. 1,253,627 shares of the stock were exchanged, compared to its average volume of 1,248,215. The stock has a market capitalization of $114.85 billion, a price-to-earnings ratio of 18.77, a price-to-earnings-growth ratio of 1.22 and a beta of 0.89. The company has a fifty day moving average price of $502.07 and a 200-day moving average price of $492.16. Elevance Health has a 1-year low of $420.73 and a 1-year high of $549.52. The company has a current ratio of 1.35, a quick ratio of 1.35 and a debt-to-equity ratio of 0.59.

Institutional Trading of Elevance Health

A number of institutional investors have recently bought and sold shares of ELV. Covestor Ltd lifted its holdings in shares of Elevance Health by 72.5% during the 1st quarter. Covestor Ltd now owns 307 shares of the company’s stock worth $151,000 after acquiring an additional 129 shares during the period. International Assets Investment Management LLC bought a new stake in shares of Elevance Health during the 1st quarter worth approximately $213,000. Engineers Gate Manager LP bought a new stake in shares of Elevance Health during the 1st quarter worth approximately $220,000. EHP Funds Inc. bought a new stake in shares of Elevance Health during the 1st quarter worth approximately $246,000. Finally, Moors & Cabot Inc. bought a new stake in shares of Elevance Health during the 1st quarter worth approximately $251,000. Institutional investors own 87.66% of the company’s stock.

Analysts Set New Price Targets

ELV has been the topic of several recent analyst reports. Mizuho boosted their price objective on shares of Elevance Health from $545.00 to $575.00 and gave the stock a “buy” rating in a research note on Thursday, November 10th. Morgan Stanley boosted their price objective on shares of Elevance Health from $485.00 to $500.00 and gave the stock an “equal weight” rating in a research note on Friday, October 21st. Wells Fargo & Company lifted their target price on shares of Elevance Health from $557.00 to $609.00 and gave the stock an “overweight” rating in a report on Wednesday, January 4th. Deutsche Bank Aktiengesellschaft lifted their target price on shares of Elevance Health from $576.00 to $581.00 and gave the stock a “buy” rating in a report on Friday, October 21st. Finally, UBS Group lifted their target price on shares of Elevance Health from $585.00 to $610.00 in a report on Monday, October 24th. One equities research analyst has rated the stock with a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Elevance Health currently has an average rating of “Buy” and an average target price of $578.89.

Elevance Health Company Profile

(Get Rating)

Elevance Health, Inc operates as a health company, which engages in improving lives and communities, and making healthcare simpler. The firm supports consumers, families, and communities across the entire care journey, connecting them to the care, support, and resources they need to lead healthier lives.